A PHASE II RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ORALLY ADMINISTERED BI 409306 DURING A 52-WEEK TREATMENT PERIOD AS AN EARLY INTERVENTION IN PATIENTS WITH ATTENUATED PSYCHOSIS SYNDROME
Principal Investigator(s)
Velligan, Dawn I
Funded by
BOEHRINGER INGELHEIM PHARMACEUTICALS
Research Start Date
Status
Active